FDA has granted regenerative medicine advanced therapy (RMAT) designation to Autolus’ CAR-T cell therapy obe-cel.
Autolus Therapeutics, a biopharmaceutical company focused on T cell therapies, announced on April 25, 2022 that FDA has granted regenerative medicine advanced therapy (RMAT) designation to its gene therapy obecabatagene autoleucel (obe-cel).
The therapy is a CD19-directed autologous chimeric antigen receptor (CAR)-T therapy meant for the treatment of adult relapsed/refractory B-Acute Lymphocytic Leukemia (B-ALL). FDA grants RMAT designation to drug candidates that may address significant unmet medical needs in patients with serious or life-threatening conditions. RMAT is designed to accelerate the drug development process by facilitating and expediting development and regulatory review. Obe-cel has been previously granted Priority Medicines (PRIME) designation by the European Medicines Agency (EMA) and Innovative Licensing and Access Pathway (ILAP) by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom.
“RMAT designation is an important regulatory milestone for obe-cel and highlights its potential to address the unmet medical need for adult patients with relapsed and refractory B-ALL,” said Dr. Christian Itin, CEO of Autolus. “RMAT designation from FDA, PRIME designation from EMA and ILAP designation from MHRA facilitate regulatory interactions with key health authorities and supports our drive to bring this innovative therapy to patients as quickly as possible.”
Source: Autolus
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.